**
In a revelation that raises significant questions about corporate influence on regulatory processes, it has come to light that senior officials from the Environmental Protection Agency (EPA) convened with Bayer’s CEO, Bill Anderson, in June of last year. This meeting, which coincided with the Trump administration’s increasing backing of Bayer in its ongoing legal battles concerning the herbicide glyphosate, highlights the complex interplay between corporate interests and public health.
Meeting Details and Context
On 17 June 2025, high-ranking officials from the EPA, including Lee Zeldin, the agency’s administrator, gathered with Anderson and other top Bayer executives to discuss pressing litigation matters. This clandestine meeting occurred shortly before the Trump administration took pivotal actions to bolster Bayer’s position regarding glyphosate, a widely used weed killer implicated in numerous cancer claims by consumers.
Litigants have accused Bayer, which acquired glyphosate producer Monsanto, of neglecting to inform users about potential cancer risks associated with its products, including the popular herbicide Roundup. As thousands of lawsuits flood the courts, the stakes for the company are immense, with settlements and jury awards costing it billions.
Central to Bayer’s legal strategy is a push for the Supreme Court to endorse its argument that it cannot be held liable for failing to warn about cancer risks if the EPA does not mandate such warnings. While some courts have sided with Bayer, multiple others have dismissed this preemption argument, a stance echoed by the Biden administration’s solicitor general.
Actions Following the Meeting
The fallout from the June meeting has been significant. Since that date, the Trump administration has taken several steps to advocate for Bayer. Notably, on 1 December 2025, D John Sauer, the solicitor general appointed by Trump, urged the Supreme Court to hear Bayer’s case, which the court subsequently agreed to, scheduling a hearing for 27 April 2026.
Moreover, in February 2026, the White House invoked the Defense Production Act to safeguard the production of glyphosate herbicides, signalling a clear endorsement of Bayer’s business interests. Just days later, Sauer submitted an amicus brief supporting Bayer’s case to the Supreme Court.
Bayer’s response to the meeting and subsequent government actions has maintained that such gatherings are routine within the regulatory framework, asserting transparency regarding its position on glyphosate litigation. The company emphasised that interactions with regulatory bodies are standard practice for various stakeholders, not limited to major corporations.
Criticism from Advocacy Groups and Legal Experts
The implications of these developments have drawn criticism from environmental health advocates and legal experts alike. Nathan Donley, the environmental health science director for the Center for Biological Diversity, expressed concern over the apparent prioritisation of corporate profits over public health. He stated, “When the CEO of one of the largest companies in the world is meeting with political appointees in a US regulatory office, it shows just how much power and influence these corporations have on decisions that can have very real consequences for the health of all Americans.”
Legal expert Whitney Di Bona echoed these sentiments, questioning the fairness of the process. “It’s concerning that the CEO of a major pesticide company can have private meetings with the EPA to talk about limiting the company’s liability,” she remarked, highlighting the disparity in access to decision-makers for ordinary citizens adversely affected by these products.
Naomi Oreskes, a professor at Harvard University, pointed out that the meeting underscores a troubling trend where industry leaders enjoy privileged access to government officials, thereby marginalising the voices of those harmed by corporate practices.
Zen Honeycutt, founder of Moms Across America, added her perspective, stating that coercion by chemical companies on regulatory agencies is a longstanding issue. She noted that despite multiple meetings with EPA leadership, her organisation has seen little action on calls to restrict harmful pesticides.
Why it Matters
The revelations surrounding the meeting between Bayer executives and EPA officials not only highlight the concerning nexus between regulatory agencies and corporate interests but also raise critical questions about the integrity of public health safeguards. As the legal battle over glyphosate unfolds, the outcomes will not only impact Bayer’s fortunes but also set a precedent for how corporations influence regulatory frameworks. The stakes are high, with the health of millions of Americans potentially hanging in the balance, illustrating the urgent need for transparency and accountability in government-corporate interactions.
